Plant-based Hemostat Powder Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Plant-based Hemostat Powder Market is projected to expand from USD 204.59 Million in 2025 to USD 358.12 Million by 2031, reflecting a compound annual growth rate of 9.78%. These absorbable, biocompatible surgical adjuncts, typically derived from polysaccharides like oxidized cellulose or potato starch, are engineered to expedite the natural coagulation process and manage arteriolar, venous, and capillary bleeding. A major catalyst for this growth is the increasing frequency of complex surgical operations and the growing global burden of chronic conditions that necessitate surgical intervention, thereby creating a critical need for efficient intraoperative hemorrhage control to reduce complications. Data from MedTech Europe indicates that in 2024, more than 63 million surgical procedures took place across Europe, underscoring the vital demand for medical technologies that uphold procedural efficiency and safety.

However, market growth faces significant obstacles due to the strict regulatory environment governing these Class III medical devices, especially concerning efficacy and safety requirements. The necessity for robust clinical evidence to satisfy complex compliance standards, such as the European Union Medical Device Regulation, establishes high entry barriers and extends approval timeframes. This regulatory weight can substantially postpone the market launch of novel plant-based hemostatic products and escalate development expenses for manufacturers, ultimately restricting the pace at which these innovations become available to the healthcare industry.

Market Drivers

The escalating global frequency of surgical procedures and trauma incidents serves as a fundamental driver for the plant-based hemostat powder market. As medical providers encounter increasing pressure to address acute injuries and clear backlogs of elective surgeries, the demand for these absorbable, biocompatible agents has intensified. These powders are particularly indispensable in high-volume trauma scenarios due to their ability to rapidly dehydrate blood and hasten clotting without the viral transmission risks inherent in animal-derived alternatives. Underscoring the magnitude of this need, the World Health Organization reported in June 2024 that injuries cause 4.4 million deaths globally each year, highlighting a vast requirement for effective bleeding control solutions. Furthermore, the volume of pending surgeries exacerbates this demand; according to NHS England, the waiting list for non-emergency treatments hit 7.6 million pathways by August 2024, indicating a substantial pipeline of operations requiring surgical consumables.

Simultaneously, the rising uptake of minimally invasive and robotic surgeries is fueling a preference for powder-based formulations over conventional textile hemostats. These flowable agents are distinctly appropriate for laparoscopic settings, as they can be accurately deployed through narrow trocars to address irregular bleeding on difficult-to-access anatomical surfaces. This technical compatibility is stimulating notable market expansion as robotic systems become more prevalent. For instance, Intuitive Surgical revealed in their October 2024 earnings report that global da Vinci procedures rose by approximately 18% year-over-year, illustrating the growing reach of robotic platforms that depend on versatile, easily applicable adjuncts such as plant-based hemostatic powders.

Market Challenges

Strict regulatory mandates concerning safety and efficacy represent a major hurdle impeding the progress of the plant-based hemostat powder market. Since these products are typically categorized as Class III medical devices due to their absorbable properties and direct contact with the bloodstream, they are subject to intense scrutiny to guarantee biocompatibility. Manufacturers are required to maneuver through intricate compliance systems that necessitate comprehensive clinical proof, a process that substantially drives up development costs and demands significant resource allocation. This financial and operational pressure establishes formidable barriers to entry, often deterring smaller enterprises from joining the market and stifling the rate of innovation within the industry.

The immediate result of these regulatory obstacles is a distinct delay in bringing products to market. Data from MedTech Europe in 2024 highlights that certifying high-risk medical devices under the Medical Device Regulation took an average of nearly 18 months, largely due to capacity limitations among notified bodies. Such extended approval periods stall the debut of new hemostatic solutions in the healthcare arena, thereby constraining manufacturers' capacity to generate income and address pressing clinical requirements in a timely manner.

Market Trends

The advancement of specialized endoscopic spray delivery systems is notably propelling the market forward by facilitating the non-invasive application of plant-based powders during gastrointestinal interventions. Manufacturers are developing catheter-based tools that pass through standard endoscopes to deposit polysaccharide powders directly onto irregular bleeding areas within the GI tract, resolving the shortcomings of mechanical clips in moist, complex anatomies. This innovation permits swift management of capillary bleeding following polypectomies or in peptic ulcers without requiring open or laparoscopic surgery. Confirming the growth of this application, Olympus Corporation announced in March 2024 that its plant-based hemostatic spray technology has been distributed across 49 U.S. states with over 5,000 kits shipped, demonstrating the swift clinical adoption of these flowable solutions in gastroenterology.

At the same time, the integration of antimicrobial qualities into plant-based formulations is becoming increasingly popular as healthcare providers aim to lower surgical site infections (SSIs) while managing hemorrhage. Industry participants are augmenting cellulose and starch-derived powders with biocompatible antimicrobial agents to produce dual-function devices that not only speed up clotting but also prevent bacterial growth at the wound site. This development directly addresses the rising economic and clinical impact of hospital-acquired infections, fueling the demand for adjuncts that uphold sterile safety standards. Emphasizing the urgency of such preventive strategies, the World Health Organization reported in November 2024 that effective infection control measures could prevent up to 821,000 deaths annually by 2050, providing a powerful incentive for the use of hemostats that actively mitigate infection risks.

Key Players Profiled in the Plant-based Hemostat Powder Market

• Ethicon Inc.
• Baxter International Inc.
• Becton Dickinson & Co
• Bioceres SA
• Grena AS/Norway
• PlantTec Medical GmbH
• Starch Medical Inc.
• Theracion Biomedical
• Singclean Medical
• Hemostasis, LLC

Report Scope

In this report, the Global Plant-based Hemostat Powder Market has been segmented into the following categories:

Plant-based Hemostat Powder Market, by Type:

• 1g
• 3g
• 5g
• Others

Plant-based Hemostat Powder Market, by Application:

• Surgical Wound Care
• General Wound Care

Plant-based Hemostat Powder Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Plant-based Hemostat Powder Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.